Clinical Trial Search

Primary: Height Velocity Standard Deviation Score (SDS) at 12-Month Endpoint — 1.83; 1.38 standard deviation score — p=0.340

Primary: Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination — 95; 99; 55; 99 Percentage of…

Primary: Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) — 53.4; 19.8 percentage of participants — p=<0.001

Primary: Onset of Effect of Vyvanse — 0.70; 1.14; 0.45; 1.42 scores on a scale — p=<0.0001

Primary: Anti-hepatitis A (HAV) Antibody Concentrations — 1122.2; 1377.8; 998.6; 1347.1 mIU/mL

Primary: Adverse Events: 12-months Safety Population — 14; 9; 1; 9 participants

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -7.23; -5.02; -9.99; -8.13 score on scale — p=0.002

Primary: Morning (AM) Peak Expiratory Flow (PEF) Rate — -21; -22 liters per minute — p=0.99

Primary: Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation — 346; 188; 121 participants

Primary: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score — -2.69; -2.31 units on a scale — p=0.617

Primary: Patient Global Rating of Pain for the Study Period (12 Weeks) — 19; 25; 27; 28 participants

Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018

Primary: Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15) — 0.49; 8.03…

Primary: FEV1 AUC0-6 at Day 85 — 0.145; 0.149; 0.119 liters — p=0.7135

Primary: Disease Free Survival (DFS) — 21.6; 24.7 months — p=0.468